Alzheimer’s Disease robs more than 5 million Americans
alone of hope for a meaningful future.
Alzheimer’s Disease mercilessly sweeps a lifetime
of memories from its victims, with devastating
impact on loved ones.
The omentum (Latin for Apron) is a protective layer
of skin that covers the abdominal organs. Omental stimulation
has demonstrated positive impact on cognitive
function for decades but has never before been
studied in a clinically meaningful way.
Cerebain Biotech’s patent-pending medical
device will used to study a minimally invasive
approach to treat Alzheimer’s Disease focusing
on the impact of omental stimulation.
Cerebain Biotech (OTC: CBBT) is dedicated to pursuing the development and commercialization of novel treatment approaches in the fight against dementias, with a particular focus on Alzheimer’s Disease.
Our vision is to apply what we know about the effect of omentum stimulation on improved cognitive function to create a new and more effective treatment paradigm. For the millions of people living with, or in fear of, an Alzheimer’s diagnosis, our success could mean hope for the future and a lifetime preserved. Our goal is the development and commercialization of a medical device with the potential to arrest or significantly slow Alzheimer’s Disease progression.
